MLTX

Kristian Reich

Known title: Chief Scientific OfficerCIK: 0001920553

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 25, 2026

MLTX noted in psoriatic arthritis market landscape report. A recent DelveInsight analysis outlined six late‑stage drugs expected to drive growth in the psoriatic arthritis market. The report highlights the expanding opportunity for immunotherapy developers, which includes companies such as MoonLake Immunotherapeutics. This broader market view may influence how investors view MLTX's pipeline prospects.

this person other insiders at MLTX

Transaction History

MLTX▼ Sell$22K
MLTX▼ Sell$49K
MLTX▼ Sell$1.0M
MLTX▼ Sell$878K
MLTX▼ Sell$322K
MLTX▼ Sell$972K
MLTX▼ Sell$935K
MLTX▼ Sell$945K
MLTX▼ Sell—
MLTX▼ Sell—
MLTX▼ Sell$1.1M
MLTX▼ Sell$2.0M
MLTX▼ Sell—
MLTX▼ Sell—
MLTX▼ Sell—
MLTX▼ Sell—
MLTX▼ Sell$1.8M
MLTX▼ Sell$1.5M
MLTX▼ Sell$1.6M
MLTX▼ Sell$1.6M
MLTX▼ Sell$31K
MLTX▼ Sell$28K
MLTX▼ Sell$575K
MLTX▼ Sell$574K
MLTX▼ Sell$602K
MLTX▼ Sell$602K
MLTX▼ Sell$602K
MLTX▼ Sell$602K
MLTX▼ Sell$624K
MLTX▼ Sell$624K
MLTX▼ Sell—
MLTX▼ Sell—
MLTX▼ Sell—
MLTX▼ Sell—
MLTX▼ Sell—
MLTX▼ Sell—
MLTX▼ Sell—
MLTX▼ Sell—

We use analytics to understand how market-wall is used. No personal data is sold.